UnitedHealth Group (UNH) — Company Research

Last Updated: 15 May 2026

UnitedHealth Group (NYSE: UNH) is the largest health insurer in the United States by revenue, operating through two complementary platforms: UnitedHealthcare, which provides health benefits to more than 50 million people, and Optum, a health services conglomerate spanning pharmacy, care delivery, and data analytics. With FY2025 consolidated revenue of $447.6 billion, the company is one of only a handful of US businesses to exceed $400 billion in annual sales. The past two years have brought extraordinary turbulence — including the fatal shooting of UnitedHealthcare CEO Brian Thompson in December 2024, a major cyberattack on subsidiary Change Healthcare in February 2024, and a collapse in GAAP earnings from $23.86 (FY2023) to $13.23 (FY2025). Despite these headwinds, the stock recovered sharply from its March 2026 lows and the underlying Optum franchise continues to expand. This report uses only verified primary-source financial data; no analyst price targets or opinions are included.

1. Company Snapshot

Field	Value
Company	UnitedHealth Group Incorporated
Ticker	NYSE: UNH
Sector	Healthcare — Managed Care
CEO	Stephen Hemsley (returned 2025; Andrew Witty stepped down)
Employees	~440,000
Revenue (FY2025)	$447.6bn (+12% YoY)
GAAP EPS (FY2025)	$13.23
Adjusted EPS (FY2025)	$16.35
Market cap (May 2026)	~$370bn
Stock price (13 May 2026)	~$399.36
52-week range	$234.60 – $404.14
Dividend/share (FY2025, est.)	~$8.69
FCF (FY2025)	$16.1bn
LT Debt, noncurrent (FY2025)	$72.3bn
Headquarters	Minnetonka, Minnesota, USA
Exchange	NYSE (S&P 500 component)

2. Bull & Bear Case

Bull Case

• Scale moat: UNH is the largest US health insurer by revenue at $447.6bn. Scale advantages translate into lower per-member administrative costs, greater negotiating leverage with hospital systems and drug manufacturers, and a nationwide network that smaller rivals cannot replicate.
• Optum diversification: Optum Health (care delivery), Optum Rx (pharmacy benefit management), and Optum Insight (healthcare data and analytics) generate over $270bn in revenue before intercompany eliminations. This diversification reduces dependence on the insurance underwriting cycle and creates recurring, fee-based income streams.
• Revenue compounding: Revenue grew from $287.6bn (FY2021) to $447.6bn (FY2025), a compound annual growth rate of approximately 12%. Growth has been driven by Medicare Advantage membership expansion, Optum Health clinic acquisitions, and pharmacy benefit management contracts.
• Value-based care infrastructure: Optum Health operates value-based care arrangements with over 4,000 employed or affiliated physicians and hundreds of clinics, positioning UNH to capture a greater share of total healthcare spend beyond pure insurance premiums.
• Dividend track record: The per-share dividend has grown steadily from ~$5.60 (FY2021) to an annualised ~$8.73 (as of FY2025), reflecting consistent cash generation despite short-term earnings volatility.

Bear Case

• Medical cost pressure: The medical care ratio rose materially in FY2024 and FY2025 due to elevated inpatient utilisation, Medicare Advantage reimbursement rates set below actual cost trends by CMS, and member mix shifts. Sustained MCR pressure is the primary driver of earnings underperformance relative to initial guidance.
• Regulatory and CMS risk: Medicare Advantage rates are determined annually by CMS and can diverge sharply from actual medical cost inflation. Any multi-year period of below-cost-trend rate updates compresses margins directly. Proposed Medicaid redeterminations and Affordable Care Act exchange mix shifts add additional uncertainty.
• Governance and reputational damage: The December 2024 fatal shooting of UnitedHealthcare CEO Brian Thompson generated unprecedented public backlash regarding insurance claim denial practices. The resulting reputational damage, leadership vacuum, and intensified regulatory scrutiny represent risks that are difficult to quantify but are structurally negative.
• GAAP EPS collapse: GAAP EPS fell from $23.86 (FY2023) to $15.51 (FY2024, including an $8.3bn loss on a South American subsidiary disposal) to $13.23 (FY2025). Adjusted EPS of $16.35 for FY2025 was far below the $29.50–$30.00 guidance issued at the start of the year, eroding near-term credibility on forecasting.
• Cyberattack and operational residuals: The February 2024 Change Healthcare ransomware attack — one of the largest healthcare cyberattacks in US history — disrupted claims processing for months, generated direct remediation costs, and may carry long-tail legal and reputational liabilities.

3. Business Segments

UnitedHealth Group operates through two primary reporting segments: UnitedHealthcare and Optum. Because Optum provides services directly to UnitedHealthcare, there are material intercompany eliminations; segment revenues therefore sum to more than the consolidated $447.6bn.

Segment	FY2025 Revenue (approx.)	% of Consolidated	What it does
UnitedHealthcare	~$344.9bn	~77%	Health benefits plans: employer-sponsored (commercial), Medicare Advantage, Medicaid managed care, and individual/ACA exchange. Largest US health insurer by membership.
Optum Health	~$105bn+	~23%	Care delivery: employed physicians, ambulatory surgery centres, home health, and value-based care arrangements. Over 4,000 affiliated physicians. Reduces insurance costs by managing care proactively.
Optum Rx	~$133bn+	~30%	Pharmacy benefit management (PBM): formulary design, drug procurement, specialty pharmacy, and mail-order fulfilment. One of the three largest US PBMs alongside CVS Caremark and Express Scripts.
Optum Insight	~$18.8bn	~4%	Healthcare data, analytics, software and revenue cycle management. Includes Change Healthcare (acquired 2022). Serves payers, providers, and government programmes. Recurring SaaS-like revenue profile.

Note: Segment revenues are pre-elimination. UnitedHealthcare and Optum transact extensively with each other; the consolidated group revenue of $447.6bn nets these out. Percentages shown are approximate and exceed 100% in aggregate due to intercompany overlap.

4. Business Model

Premium revenue and the insurance underwriting engine. UnitedHealthcare collects premiums from employers, government programmes (Medicare and Medicaid), and individuals. The core profitability metric is the Medical Care Ratio (MCR) — medical costs divided by premiums. A lower MCR signals better underwriting discipline. In FY2023, UNH maintained an MCR near 83–84%, a historically strong level. In FY2024–FY2025, MCR deteriorated due to higher-than-expected Medicare Advantage inpatient utilisation and CMS rate pressure, compressing margins.

Medicare Advantage as the growth engine. Medicare Advantage (MA) is the fastest-growing segment of US healthcare. CMS pays insurers a risk-adjusted capitation rate per member per month. UNH has historically been among the most efficient operators in MA, but the mismatch between CMS rate updates and actual medical cost inflation in 2024–2025 eroded this advantage. MA membership growth remains the primary long-run volume driver.

Optum cross-sell and vertical integration. Optum creates value by capturing medical cost dollars that would otherwise flow to third-party providers. Optum Health employed physicians can manage chronic conditions more cost-effectively than fee-for-service arrangements, reducing total cost of care for UnitedHealthcare's insured population. Optum Rx's formulary management captures rebates and drug cost savings. Optum Insight monetises claims data through analytics and software licensing. Each Optum dollar of revenue is partly self-funded through UnitedHealthcare membership — creating a vertically integrated managed care unit economy that competitors without a comparable health services arm cannot match.

Value-based care and shared savings. Under value-based care contracts, Optum Health physicians receive capitated payments rather than fee-for-service reimbursement, with shared savings if outcomes improve and total cost falls below benchmarks. This aligns physician incentives with insurer cost management and generates recurring operating leverage as the patient panel grows.

Unit economics and cash generation. Even in a compressed-margin year, UNH generated $19.7bn in operating cash flow in FY2025. The company's capital-light insurance model means that cash conversion (operating cash flow relative to revenue) remains high despite the scale of operations. Free cash flow of $16.1bn in FY2025, after $3.6bn in capex, funds dividends (~$8.1bn run rate), share repurchases, and ongoing Optum acquisitions.

5. Financial Health

The five-year trend below shows revenue, earnings, dividends, and balance sheet metrics from primary SEC filings. All figures in USD millions unless noted. Free Cash Flow = Operating Cash Flow minus Capital Expenditure (e.g. FY2025: $19,697M − $3,622M = $16,075M). Long-term debt figures are the noncurrent balance sheet line ("Long-term debt, less current maturities") from each year's SEC 10-K or 8-K filing.

Year	Revenue ($M)	YoY %	GAAP EPS	Adjusted EPS	Dividend/share	LT Debt (noncurrent, $M)
FY2021	$287,597	—	$18.08	$19.02	~$5.60	$42,383
FY2022	$324,162	+12.7%	$21.18	$22.19	~$6.40	$54,513
FY2023	$371,622	+14.6%	$23.86	$25.12	~$7.21	$58,263
FY2024	$400,278	+7.7%	$15.51	$27.66	~$8.11	$72,359
FY2025	$447,567	+11.8%	$13.23	$16.35	~$8.69	$72,320

FY2024 GAAP EPS note: The $15.51 GAAP EPS includes an approximate $8.3bn loss on the disposal of a South American subsidiary (Banmedica). Adjusted EPS of $27.66 excludes this item. FY2025 GAAP EPS note: The $13.23 figure reflects elevated medical care ratios, Change Healthcare remediation costs, and other charges. Adjusted EPS of $16.35 excludes amortisation of intangibles and certain non-recurring items but still represents a significant miss against initial FY2025 guidance of $29.50–$30.00.

Cash flow and capex detail (FY2023–FY2025):

Metric ($M)	FY2021	FY2023	FY2024	FY2025
Operating Cash Flow	$22,343	$29,068	$24,204	$19,697
Capital Expenditure	$2,454	$3,386	$3,499	$3,622
Free Cash Flow	$19,889	$25,682	$20,705	$16,075
D&A	$3,103	$3,972	$4,099	$4,361

Quarterly revenue trend (FY2024, most recent available with quarterly detail):

Quarter	Revenue	GAAP EPS	Adjusted EPS
Q4 2024	$100.8bn	$5.98	$6.81
Q3 2024	~$100.8bn	~$4.20	~$7.15
Q2 2024	~$98.9bn	~$1.90	~$6.80
Q1 2024	~$99.8bn	~$3.43	~$6.91
FY2024 (full year)	$400.3bn	$15.51	$27.66

6. Valuation

Market data as at 13 May 2026. Enterprise value calculated as: market cap ($370bn) + total debt ($78.4bn) — cash and short-term investments ($28.1bn) ≈ $420bn. EV/EBITDA of ~16.5x sourced from market data providers (GuruFocus). Trailing P/E on GAAP EPS is elevated due to extraordinary charges; the adjusted P/E of ~24.5x better reflects underlying earnings power.

Metric	Value	Notes
Market cap	~$370bn	At ~$399/share, ~927M diluted shares
Enterprise value	~$420bn	Mkt cap + $78.4bn total debt − $28.1bn cash
Trailing P/E (GAAP)	~30.2x	$399 / $13.23 FY2025 GAAP EPS; distorted by extraordinary charges
P/E (forward)	~24.5x	$399 / $16.35 FY2025 Adjusted EPS
P/S (TTM)	~0.83x	$370bn / $447.6bn FY2025 revenue
EV/EBITDA (TTM)	~16.5x	Source: market data providers (GuruFocus, May 2026)
P/FCF	~23x	$370bn / $16.1bn FY2025 FCF
52-week high	$404.14	May 2026 as of report date
52-week low	$234.60	Reached approximately March 2026
Short interest (% of float)	1.64%	Source: market data, May 2026
Days to cover	~1.83	Based on average daily volume

For live technical signals, see the ChartsView live charts tool. For macro context that affects healthcare valuations (interest rates, risk-on/off), see the economic calendar.

7. What Are They Building

Medicare Advantage growth and profitability restoration. CMS rate announcements for 2026 and 2027 are the single most important near-term value driver. UNH has signalled it intends to stabilise its MA book through a combination of benefit design resets, risk coding improvements, and selective membership management. The company's scale in MA — millions of members — means that even a 100 basis point improvement in MCR translates to approximately $3–4bn in incremental operating income.

Optum Health clinic and physician network expansion. Optum Health has been acquisitively building a national network of primary care clinics, specialist practices, and ambulatory surgery centres. The long-term thesis is that owning the point of care allows UNH to manage total cost of care rather than just paying claims — a fundamentally more defensible and higher-margin model. Management has guided that Optum Health will progressively grow its share of total group revenue.

AI in prior authorisation and utilisation management. UNH, through Optum Insight's technology stack, has been developing and deploying AI-assisted prior authorisation tools. These aim to reduce the administrative burden of authorisation decisions while improving clinical consistency. Given the intense public and regulatory scrutiny on prior auth practices following the December 2024 events, any AI deployment in this area will face heightened Congressional and CMS oversight through 2026.

Change Healthcare recovery and Optum Insight rebuild. The February 2024 cyberattack on Change Healthcare disrupted Optum Insight revenue and required significant remediation investment. Management is rebuilding the platform's security architecture and working to restore full customer functionality. Successful recovery would restore an important recurring revenue stream and reduce residual operational risk.

FY2026 guidance and earnings rebuild. UNH withdrew its FY2026 earnings guidance in early 2025 due to uncertainty around medical cost trends. The company indicated it would provide updated guidance with Q1 2026 results (expected around April–May 2026). Restoration of credible guidance and a path back toward adjusted EPS in the mid-to-high $20s would be a significant positive catalyst for the stock, which recovered ~47% from its March 2026 trough.

8. Competitive Landscape

UnitedHealth Group competes primarily in US managed care (health insurance) and health services. Its scale is significantly larger than any direct competitor. The following peers are included for comparison; revenue figures from company filings and press releases.

Peer	Market Cap (May 2026)	FY2025 Revenue	P/E (TTM, May 2026)	Primary differentiator
UnitedHealth Group (UNH)	~$370bn	$447.6bn	~30x GAAP / ~24.5x Adj	Scale leader; vertically integrated Optum health services platform
Elevance Health (ELV)	~$86.8bn	~$199.1bn	~10–12x	Blue Cross Blue Shield licensee network; Medicaid and commercial focus
CVS Health (CVS)	~$124.3bn	~$370bn	~12–15x	Integrated pharmacy, PBM (Caremark), Aetna insurance and MinuteClinic retail health
Cigna Group (CI)	~$77.85bn	~$250bn est.	~10–12x	Express Scripts PBM; international and specialty benefits focus
Humana (HUM)	~$23.07bn	$129.7bn	N/M (earnings pressure)	Pure-play Medicare Advantage; high MA membership concentration

Centene (CNC) is also a significant Medicaid managed care competitor; the company reported a loss for FY2025 and is therefore not included in the P/E comparison. Discuss these companies and others in the ChartsView forum.

9. Leadership & Insider Ownership

Current CEO: Stephen Hemsley (returned to the chief executive role in 2025 following the resignation of Andrew Witty, who stepped down citing personal reasons). Hemsley previously served as CEO from 2006 to 2017 and is the architect of UNH's Optum strategy. He joined the company in 1997 and has a deep institutional knowledge of the business.

Brian Thompson context: Brian Thompson, CEO of UnitedHealthcare (the insurance subsidiary), was fatally shot in New York City on 4 December 2024. This event led to intense public scrutiny of UNH's claims denial practices and contributed to significant senior management instability throughout 2025.

Recent insider transactions (SEC Form 4 filings):

Name	Date	Type	Shares	Price	Value	Plan Type
Stephen Hemsley (CEO)	17 Mar 2026	Grant (dividend equiv. on deferred stock units)	61	—	—	Non-discretionary
Stephen Hemsley (CEO)	19 Dec 2025	Gift (discretionary)	55,000	—	—	Discretionary gift
Paul R. Garcia (Director)	01 Apr 2026	Grant (quarterly Board compensation)	206 DSUs + 137	—	—	Board compensation
Michele J. Hooper (Director)	01 Apr 2026	Grant (quarterly Board compensation)	206 DSUs	—	—	Board compensation
Kristen Gil (Director)	01 Apr 2026	Grant (quarterly Board compensation)	320 DSUs	—	—	Board compensation

No open-market purchases or discretionary insider sales have been identified in the most recent 12-month period based on available SEC Form 4 filings. All transactions above are non-market grants or non-discretionary events.

10. Key Risks

• Medical care ratio deterioration: The most direct earnings risk. If inpatient utilisation rates remain elevated and CMS Medicare Advantage rates do not adequately compensate, MCR stays elevated and adjusted EPS cannot recover toward historical levels. There is limited short-term ability to reprice insurance contracts once membership year begins.
• CMS reimbursement and regulatory risk: CMS sets Medicare Advantage capitation rates annually. Multi-year periods of below-medical-cost-trend rate increases — such as those experienced in 2024–2025 — directly compress margins. Medicaid redeterminations and potential ACA exchange rule changes add further regulatory uncertainty.
• Reputational and political risk: The public reaction to the December 2024 shooting and ongoing scrutiny of claim denial practices have elevated political risk around managed care business practices. Congressional hearings, state-level legislative proposals on prior authorisation, and potential federal regulation of claim processing could increase administrative burdens and constrain benefit design flexibility.
• Change Healthcare cyberattack residuals: The February 2024 ransomware attack on Change Healthcare generated direct financial costs of several billion dollars. Long-tail risks include class action litigation from affected healthcare providers, regulatory fines, and continuing security investment requirements. The incident demonstrated systemic fragility in UNH's data infrastructure.
• Leadership transition execution risk: The return of Stephen Hemsley as CEO and the broader management reset following the December 2024 events creates near-term execution risk. Rebuilding management teams, restoring employee morale, and re-establishing credibility with investors and regulators requires sustained execution over multiple years.
• Balance sheet and debt levels: Total debt reached $78.4bn in FY2025, with noncurrent long-term debt of $72.3bn. While cash generation supports debt servicing, rising interest rates increase the cost of refinancing and limit financial flexibility for acquisitions. Net debt/EBITDA is elevated relative to the company's pre-2022 leverage profile.
• Antitrust and M&A regulatory risk: Optum's vertical integration model has drawn scrutiny from DOJ and FTC regarding potential anti-competitive practices in hospital/physician acquisitions and data access. Future M&A activity may face longer review processes or divestiture requirements.

11. Recent Developments

• 05 May 2026 — Insurers show recovery in Q1 2026. CNBC reported that UnitedHealth, Cigna, and Humana all delivered Q1 2026 earnings that suggested a partial recovery in managed care margins. The sector had been under sustained pressure since early 2024 due to elevated Medicare Advantage utilisation.
• 13 May 2026 — UNH stock recovers ~47% from March 2026 lows. The stock traded near $399, up approximately 47% from trough levels of around $270 reached in March 2026. The recovery reflected improving sentiment around medical cost trends and anticipation of updated FY2026 guidance.
• Early 2025 — FY2026 guidance withdrawn. UnitedHealth Group withdrew its FY2026 earnings guidance due to uncertainty surrounding medical cost trends and the ongoing aftermath of the Change Healthcare cyberattack. The company stated it would provide updated guidance alongside Q1 2026 results.
• 15 Jan 2025 — FY2024 results reported. UNH reported FY2024 revenue of $400.3bn and GAAP EPS of $15.51, below prior-year GAAP EPS of $23.86. The decline reflected an $8.3bn loss on disposal of the South American (Banmedica) subsidiary and elevated medical care ratios. Adjusted EPS of $27.66 was also below initial guidance ranges.
• 04 Dec 2024 — Brian Thompson fatally shot. Brian Thompson, CEO of UnitedHealthcare (the insurance subsidiary), was shot and killed outside a healthcare conference in New York City. The event generated widespread public debate about US health insurance practices and resulted in intense scrutiny of UNH's claim denial rates. Andrew Witty subsequently stepped down as group CEO; Stephen Hemsley returned to lead the company.
• Feb 2024 — Change Healthcare cyberattack. A ransomware attack on Change Healthcare (an Optum Insight subsidiary acquired in 2022) disrupted claims processing across the US healthcare system for an extended period, affecting thousands of hospitals, pharmacies, and physician practices. UNH disclosed direct costs of several billion dollars related to remediation and provider support.

12. Key Upcoming Dates

• 15 Jul 2026 — Q2 2026 earnings (estimated; UNH typically reports quarterly results mid-month following quarter end. Exact date unconfirmed as of report date).
• TBC 2026 — FY2026 guidance update (expected to be provided with Q1 2026 results announcement).
• TBC 2026 — Annual General Meeting / Shareholder Meeting (typically held in June each year).
• TBC Sep 2026 — Q3 2026 earnings (estimated; typically mid-October).

Track earnings dates and dividend announcements on the ChartsView economic calendar. Discuss the UNH investment case with other members on the ChartsView forum. See more research on the ChartsView research blog.

---

Disclaimer: This article is provided for educational and informational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. All financial data is sourced from primary SEC filings and company press releases as cited. Market data (price, market cap, valuation multiples) reflects publicly available information as at 13–15 May 2026 and may have changed. Past financial performance is not necessarily indicative of future results. ChartsView does not hold any position in UNH securities. Readers should conduct their own independent research and consult a qualified financial adviser before making any investment decisions.